Articles tagged with Tumor Growth
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers at the University of Gothenburg have identified a protein called HnRNPK that controls tumor growth by binding to messenger RNA, potentially enabling the development of new cancer drugs with fewer side effects.
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
Researchers at Kyoto University have developed a cancer therapy model that utilizes a protein degrading system to transiently degrade and reduce the PD-1 protein, which blocks immune function. This approach has shown high therapeutic efficacy in inhibiting cancer cell growth in mice.
A study found that cold temperatures activate brown adipose tissue that competes with tumors for glucose, inhibiting tumor growth and prolonging survival. Researchers suggest that cold therapy could be a promising approach to cancer therapy.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
A team of researchers has discovered that malignant tumors accumulate lipid delivery molecules called LDL and attract immune suppressor cells called neutrophils, leading to tumor progression. The study also shows that targeting the LOX-1/oxidized LDL axis may be a promising strategy for treating both cancer and cardiovascular disease.
Researchers have found that treating high-grade squamous intraepithelial lesions (HSILs) in people with HIV significantly decreases the progression to anal cancer. The ANCHOR trial enrolled over 4,000 participants and showed a 57% reduction in anal cancer cases.
Researchers discover G6PD's pivotal role in activating pentose phosphate pathway to counter oxidative stress, leading to increased cell death and tumor shrinkage. Ovarian cancer cells' reliance on fatty acid metabolism fuels oxidative compound production, which can be offset by G6PD inhibition.
A study by Michigan Medicine researchers has identified oncostreams, highly active cells connected to brain tumor growth and invasion. The team found that eliminating Collagen 1 production from tumor cells reduces tumor aggressive behavior. This discovery could lead to novel therapeutic targets for treating lethal brain tumors.
Researchers at Cold Spring Harbor Laboratory have discovered a way to regulate plant growth by manipulating proteins called UBP12 and UBP13, which helps control the amount of CRY2 photoreceptor in plants. This finding has potential applications in improving crop yields and informing cancer research.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
Research describes how breast cancer cells impair pancreatic islet function to suppress insulin production, leading to diabetes and increased tumor growth. The study identifies microRNA-122 as a key player in this process.
Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.
A new interactive web portal, SpUR, catalogues over 1,000 splicing events found in cancers, highlighting their role in tumor development and progression. The database provides a platform for researchers to study RNA dysregulations in cancer and develop RNA-based anti-cancer drugs.
Scientists have discovered a small molecule that bypasses ADAR1 suppression and directly activates tumor cell death by ZBP1, inducing highly immunogenic cell death and destroying fibroblasts supporting tumor growth. This approach has the potential to improve the effectiveness of immunotherapy in treating therapy-resistant tumors.
Researchers have developed biodegradable nanovesicles that efficiently encapsulate and deliver PARP1 siRNA to breast cancer tumors in mice, inhibiting oncogene expression and extending survival. The polymersomes, assembled from three biodegradable block copolymers, have strong potential for precision-targeted therapeutic carriers.
A new study found that crown-like structures surrounding breast tumors in overweight and obese patients can hinder their response to therapy. Researchers identified a potential molecular biomarker, CD32B, which is associated with poorer treatment outcomes.
A Brazilian group developed a peptide called Rb4 that triggers necrosis in murine melanoma cells and inhibits the viability of human cancer cells. In mice, Rb4 reduced lung metastasis and slowed subcutaneous melanoma growth, increasing survival by 25%.
Researchers at Ohio State University Wexner Medical Center have discovered a new molecular drug target to treat cancer, VEGF-A, which can increase expression of dopamine D2 receptors on endothelial cells to stop blood vessel growth and spread diseases like colon cancer and ovarian hyperstimulation syndrome.
Researchers discovered that neurons carrying a mutation in the Nf1 gene are hyperexcitable and suppressing this hyperactivity with lamotrigine stops tumor growth in mice. The study provides an explanation for why some people with NF1 lack optic gliomas or neurofibromas, highlighting the critical role of neurons in tumor biology.
A UC Davis study found a critical agent keeping KSHV dormant and undetected by the immune system. The virus is linked to various cancers and AIDS-related diseases. The researchers identified CHD4 as a key regulator of the latency-lytic switch, allowing the virus to stay silent.
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Case Western Reserve University discovered that altering macrophage metabolism influences their relationship with T cells, suppressing tumor growth and reducing overall tumor size. The study found PERK protein's involvement in key metabolic pathways and identified a potential clinical drug inhibitor to target it.
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
A study by MedUni Vienna reveals that mutations in the KMT2C protein lead to increased cell division, driving metastatic prostate cancer. This discovery may enable early diagnosis through a blood test and treatment with MYC inhibitors.
Researchers have discovered two distinct classes of cancer-associated fibroblasts that accumulate in the pancreatic tumor microenvironment and play opposing roles. The study suggests that targeting these unique cell populations may improve treatment outcomes for pancreatic cancer patients.
Researchers at Karolinska Institutet identified a novel protein mechanism that inhibits tumour growth in ER-negative breast cancer, leading to improved prognosis. High levels of GIT1 were associated with reduced tumour growth and better outcomes in ER-negative patients.
Researchers developed a novel genetic barcode system to mark cancer cells with different gene modifications and image their characteristics. The Perturb-map platform identified specific genes controlling lung tumor growth, immune composition, and response to immunotherapy, offering new approaches for targeting anti-cancer drugs.
Researchers at Massachusetts General Hospital found that using nanomedicines at lower, more frequent doses can normalize the tumor microenvironment and improve cancer treatments. The study showed that this approach can help correct abnormalities that protect tumors and improve blood vessel function and immune activation within a tumor.
Researchers found that the Klotho gene can suppress glioblastoma cell viability and induce apoptosis, leading to a significant decrease in tumor growth. The study contributes to the development of new diagnostic and treatment approaches for malignant brain tumors.
A team from UNIGE has identified a potential target for restoring the efficacy of standard breast cancer treatment. The loss of SPRED2 protein leads to tumor proliferation even with tamoxifen treatment. Combining tamoxifen with an inhibitor of estrogen-independent cell activation may be promising for resistant patients.
Researchers at UCSF develop a new cancer treatment that targets RAS-mutated tumors by exploiting their high levels of ferrous iron. The treatment, TRX-cobimetinib, is more effective and tolerable than current treatments like cobimetinib, which can cause serious side effects in normal tissues.
Researchers at Tokyo University of Science have developed bionanoparticles derived from corn that selectively target and inhibit the growth of cancer cells, inducing tumor necrosis factor-α release. These findings suggest a novel, economical, and safe anti-cancer therapy approach.
A comprehensive analysis of over 2,200 patients in Europe reveals the complexity of cholangiocarcinoma, a rare cancer often diagnosed at an advanced stage. The study highlights the need for education programs to raise awareness and improve early diagnosis, survival, and quality of life.
A University of Illinois study discovered that cadherin proteins can sense mechanical stress and alter cell communication, promoting tissue growth and tumorigenesis. The findings suggest a potential mechanism for preventing certain types of tissue growth by mutating cadherin molecules.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
Researchers at Massachusetts General Hospital developed a safe and effective strategy to treat glioblastoma using short bursts of radiation therapy and nanoparticle-based immunotherapy. The combined approach suppresses tumor growth, induces anti-tumor immunity, and prolongs survival in animal models.
Researchers found that hyaluronic acid is not only present in pancreatic tumors but also serves as a nutrient source for cancer cells. This discovery indicates potential new treatments for pancreatic cancer by targeting the sugar scavenging pathway.
Researchers at Osaka University have made a breakthrough in understanding the molecular mechanisms behind Intrahepatic cholangiocarcinoma (ICC), a deadly form of liver cancer. By identifying TRAF3 and NIK as key players, they have uncovered potential therapeutic targets for novel ICC treatment.
Researchers found that zika virus injections destroyed brain tumors in mice and reduced tumor size in cerebral organoids, with immune cells alerting the system to its existence. This approach opens up prospects for virotherapy treatment of central nervous system tumors.
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
Researchers found that asthma causes immune cells to behave in a way that prevents brain tumor growth, suggesting a potential new therapeutic approach. The findings suggest reprogramming T cells to act like those in asthma patients could be a new treatment for brain tumors.
Researchers at the University of Gothenburg have successfully treated high-risk neuroblastoma in mice using a combination of precision medicines, showing potential for a curative treatment. The study's results suggest that patients with this form of childhood cancer may benefit from drug treatment with ATR inhibitors.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
The Lef1 gene is found to suppress the development and growth of colorectal cancer by restricting cancer stem cell niches. Blocking this gene leads to increased tumor stem cell niches and accelerated tumor growth.
According to experts, half of patients with two common subtypes of advanced breast cancer may live for five years or longer. The new guidelines also aim to improve treatment options for triple-negative breast cancer patients.
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).
Metastases in malignant melanoma can use an alternative process to access the circulatory system, where a blood vessel divides into two parallel vessels. This finding challenges traditional research on tumor growth and may lead to new treatment options for metastatic cancer.
Researchers at MIT develop a method to decode images of cells in a tissue to determine its phase, which can indicate its developmental stage or cancer progression. The technique uses triangular order parameters to characterize tissue states, allowing for quicker and less invasive diagnoses.
A new study finds that high-dose radiation therapy can lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted tumor growth or spread. Stereotactic body radiation therapy (SBRT) shows promise in treating oligoprogressive, metastatic lung and breast cancer.
A new study from MIT reveals that calorie-restricted diets slow tumor growth in mice by reducing fatty acid availability, while ketogenic diets have limited effect. The findings offer insight into how dietary interventions might be combined with existing or emerging drugs to help patients with cancer.
A novel therapy concept allows tumor cells to produce a protein that blocks CD47 and activates immune cells. This approach eradicates tumors by macrophage and NK cell activation in a highly malignant human breast cancer model.
A peptide-drug conjugate called CBX-12 has been shown to enhance the efficacy of immune checkpoint inhibitors in preclinical cancer models by targeting the acidic environment of cancer cells. The treatment exhibited significantly delayed tumor growth, improved survival, and complete tumor regressions compared to immunotherapy alone.
A clinical trial found that obese prostate cancer patients who underwent regular exercise training for 12 weeks had increased levels of anti-cancer myokines, which suppressed tumour growth and helped fight cancerous cells. The study suggests exercise may be a key weapon in cancer patients' battle against the disease.